AstraZeneca Pharma India Ltd

ESG rating disclosure

• Crisil ESG Ratings assigned an ESG score of 57 for the company based on publicly available information.
• The company did not engage Crisil ESG Ratings; rating prepared independently.
• ESG rating disclosed under SEBI LODR Regulation 30.

Meeting Details

• Date: August 26, 2026; one-on-one, virtual meeting with institutional investor.

Participants

• Company participants' roles not disclosed.

Purpose

• Purpose: one-on-one investor interaction with an institutional investor.

Meeting Details

• Date: August 19, 2026; Type: one-on-one; Mode: virtual; Interaction: institutional investor
• Organiser: AstraZeneca Pharma India Limited

Participants

• Company participants: Company Secretary & Compliance Officer

Purpose

• Purpose: investor interaction

AGM Details

• AGM held on August 10, 2026 via Video Conferencing/Other Audio Visual Means.
• Scrutinizer’s report dated August 11, 2026; all resolutions passed with requisite majority.

Financial highlights

• Total revenue from operations rose 30% YoY to INR 6,828 Mn in Q1 FY2026-27.
• Profit before exceptional item and tax: INR 510 Mn.
• Profit before tax (stated as 'profit after exceptional item and tax' per note): INR 507 Mn.

Regulatory approvals and milestones

• Acalabrutinib approved in CLL/SLL in combination with venetoclax with/without obinutuzumab.
• Acalabrutinib approved in MCL in combination with bendamustine and rituximab.
• Trastuzumab deruxtecan approved in combination with pertuzumab for first-line HER2+ breast cancer.

Strategic initiatives

• MoU with Government of Telangana to deploy AI-enabled lung cancer screening.
• Launched K+ Connect for hyperkalaemia management in heart failure and CKD.
• Launched India Coronary Conquest 2026 with STEMI India for PCI learning.

Recognitions

• OPPI India Awards 2026: Medical Excellence Award for Rare Disease.
• Runner-up in Marketing Excellence for Hyperkalaemia & Kidney Care initiative.
• ETHRWorld Gold Award for Exceptional Employee Experience Driving Business Impact.

Note on metrics and outlook

• No explicit financial guidance issued for FY2026-27.
• Note clarifies metric interpretation: 'Profit after exceptional item and tax' read as 'Profit before tax' per the filing.

AGM details

• Quorum not present at the scheduled start; AGM proceeded via VC/OAVM.
• Remote e-voting opened before the meeting; additional e-voting allowed during AGM.

Key resolutions

• Adoption of financial statements and boards' and auditors' reports.
• Dividend on equity shares declared.
• Re-appointment of director retiring by rotation.
• Appointment of statutory auditors.
• Re-appointment of independent director for a second five-year term.

Voting results

• Voting results awaited pending Scrutinizer’s report.

Financials

• Q1 FY2026-27 total revenue from operations INR 6,828 Mn, up 30% YoY.
• Profit before exceptional item and tax INR 510 Mn.
• Profit after tax INR 507 Mn.
• Oncology revenue 4,649 Mn; Biopharmaceuticals 1,619 Mn (+36%); Rare 144 Mn (+35x).

Board actions

• Unaudited results for quarter ended June 30, 2026 approved.
• Arun Krishna appointed Additional Director (Non-Executive) from Aug 17, 2026.
• Bhavana Agrawal designation changed to Non-Executive Director from Sept 1, 2026.

Strategic initiatives

• Telangana MoU for AI-enabled lung cancer screening across 20 facilities.
• K+ Connect launched for hyperkalaemia management in heart failure and CKD.
• India Coronary Conquest 2026 launched with STEMI India to advance cardiovascular care.

Awards & recognitions

• OPPI 2026: Medical Excellence Award for Rare Disease; Marketing Excellence runner-up for Hyperkalaemia/Kidney Care.
• ETHRWorld Gold Award for Exceptional Employee Experience in Driving Business Impact.

Regulatory update

• On August 7, 2026, CDSCO/DG Health Services granted import for sale and distribution of Enhertu for added indication.
• Indication: adjuvant treatment for adult HER2-positive breast cancer with residual disease post-neoadjuvant therapy.
• Brand: Enhertu; 100 mg/5 mL lyophilized powder for concentrate for infusion.
• Subject to related statutory approvals; marketing in India envisaged pending those clearances.

NPPA demand update

• NPPA demand notice for alleged overcharging under DPCO 2013; amount Rs 1,48,65,83,590 incl. interest.
• Notice dated July 29, 2026; payment due within 30 days.
• Period of alleged violations: May 2016 to November 2025.
• Company evaluating the notice and potential legal actions.
• Impact on financials pending; no definitive impact disclosed.

Reg 74(5) compliance actions

• Securities dematerialised are listed on the stock exchange(s) where the earlier issued securities are listed.
• Mutilated and cancelled the certificate of security forwarded by the participants.
• Substituted the depository’s name as registered owner in our records.